Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01518192 |
Recruitment Status
:
Completed
First Posted
: January 25, 2012
Results First Posted
: January 25, 2012
Last Update Posted
: January 25, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Background:
- While doxycycline is a standard antibiotic for treatment of erythema migrans in Europe as well as in the USA, the effectiveness of cefuroxime axetil in the treatment of adult patients with erythema migrans has been assessed only in the USA where the causative agent of Lyme disease is Borrelia burgdorferi, but not in Europe where the main etiologic agents are B. afzelii and B. garinii.
- Controversy exists over the significance and even the existence of post-Lyme disease symptoms because of the high rate of similar background symptoms in the general population.
Purpose:
The two main purposes of this European, prospective clinical trial in which doxycycline and cefuroxime axetil are compared in the treatment of adult patients with erythema migrans and which included a control group to address the significance of post-Lyme disease symptoms are:
- To assess and compare the effectiveness of doxycycline and cefuroxime axetil in the treatment of erythema migrans using clinical and bacteriological criteria (noninferiority testing approach), and
- to compare the frequency of post-Lyme disease symptoms in adult patients treated for EM with antibiotics and the frequency of similar symptoms in control subjects without Lyme disease.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erythema Migrans Post-Lyme Disease Symptoms | Drug: doxycycline Drug: cefuroxime axetil | Phase 4 |
Sample size
Decisions were based on the following:
- Number of patients with erythema migrans treated with doxycycline and cefuroxime axetil was determined assuming no difference in treatment outcome will be detected (non-inferiority testing).
-
The decision for a larger sample sizes than needed for 1. was done with the intention to evaluate the secondary outcome measure, i.e., to assess the difference between the frequency of new or increased symptoms in patients treated for early Lyme disease and the occurrence of the same symptoms in control subjects.
- We assumed that the outcomes in the two treatment groups will be comparable and that the patients could be combined for further analysis.
- To obtain a control group from the same geographical area, each patient was asked if she or he had a family member or friend who was within 5 years of her or his age and who was without a history of Lyme borreliosis. These persons were approached by a short written explanation of the investigation, containing also a request for their participation. We assumed that we will be able to get a corresponding control person not for all but for approximately 80-90% of patients.
- Under the assumption that approximately 15% of an estimated 200 patients would have new or increased symptoms at >6 months after enrollment into the study, a control group of 165 subjects would be sufficient to detect a >10 percentage point lower rate of new or increased symptoms in controls compared with patients at the 0.05 level (2-sided) with >90% power. To comply with drop outs at different time points we assessed that 280 patients and 230 controls should be included at baseline.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 544 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome. |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | November 2007 |
Actual Study Completion Date : | January 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1Doxycycline |
Drug: doxycycline
100 mg bid; 15 days
|
Active Comparator: 2 Cefuroxime axetil |
Drug: cefuroxime axetil
500 mg bid; 15 days
|
- Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days [ Time Frame: at 14 days post inclusion ]Number of patients with objective manifestations of Lyme disease(persistence of erythema migrans or any of the extracutaneous-cardiac, nervous or skeletal-Lyme disease manifestations)and/or with post-Lyme disease symptoms in patients treated for solitary erythema migrans at 14 days post inclusion
- Adverse Events [ Time Frame: at 14 days ]Number of patients reporting adverse events
- Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 2 Months [ Time Frame: 2 months ]Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 2 months post inclusion
- Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 6months [ Time Frame: 6 months ]Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 6 months post inclusion
- Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 12 Months [ Time Frame: 12 months ]Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 12 months post inclusion
- New or Increased Symptoms Since Erythema Migrans in Patients and Controls at 6 Months. [ Time Frame: 6 months ]Comparison of the number patients and controls with new or increased symptoms since erythema migrans at 6 months.
- New or Increased Symptoms Since Erythema Migrans in Patients Controls at 12 Months. [ Time Frame: 12 months ]Comparison of the number of patients and controls with new or increased symptoms since erythema migrans at 12 months.
- Selected Subjective Symptoms in Patients and Control Subjects [ Time Frame: Examination at 12 months ]Comparison of the number of patients and controls with selected 8 symptoms (fatigue, arthralgias, myalgias, headache, paresthesias, dizziness, irritability, or nausea) within the preceding week, irrespective of whether they were new or increased since erythema migrans.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- patients 15 or more years old
- with typical erythema migrans
- evaluated between 6/06 and 9/06
- evaluated at the Lyme Disease Outpatient Clinic, University Medical Center Ljubljana, Slovenia.
Exclusion Criteria:
- history of Lyme disease in the past
- pregnancy
- lactation
- immunocompromising condition
- history of a serious adverse reaction to a beta-lactam or tetracycline drug
- receiving an antibiotic with known anti-borrelial activity within 10 days
- multiple erythema migrans lesions or an extracutaneous manifestation of Lyme disease.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01518192
Slovenia | |
Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana | |
Ljubljana, Slovenia, 1000 | |
Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia | |
Ljubljana, Slovenia, 1525 |
Principal Investigator: | Daša Cerar, MD | Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia | |
Study Chair: | Franc Strle, MD | Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia |
Responsible Party: | Franc Strle, M.D., PhD, University Medical Centre Ljubljana |
ClinicalTrials.gov Identifier: | NCT01518192 History of Changes |
Other Study ID Numbers: |
EM-DC |
First Posted: | January 25, 2012 Key Record Dates |
Results First Posted: | January 25, 2012 |
Last Update Posted: | January 25, 2012 |
Last Verified: | December 2011 |
Keywords provided by Franc Strle, University Medical Centre Ljubljana:
erythema migrans doxycycline cefuroxime axetil post-Lyme disease symptoms background symptoms in general population |
Additional relevant MeSH terms:
Lyme Disease Borrelia Infections Erythema Erythema Chronicum Migrans Glossitis, Benign Migratory Skin Diseases Gram-Negative Bacterial Infections Bacterial Infections Tick-Borne Diseases Spirochaetales Infections Skin Diseases, Bacterial Skin Diseases, Infectious Infection |
Glossitis Tongue Diseases Mouth Diseases Stomatognathic Diseases Doxycycline Cefuroxime Cefuroxime axetil Anti-Bacterial Agents Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents |